Hypera S.A. (HYPMY) Q3 2026 Earnings Call October 28, 2026 10:00 AM EDT
Company Participants
Breno Pires de Oliveira – Chief Executive Officer
Ramon Frutuoso Silva – CFO & Investor Relation Officer
Conference Call Participants
Vinicius Strano – UBS Investment Bank, Research Division
Joseph Giordano – JPMorgan Chase & Co, Research Division
Vinicius Figueiredo – Itaú Corretora de Valores S.A., Research Division
Robert Ford – BofA Securities, Research Division
Samuel Alves – Banco BTG Pactual S.A., Research Division
Gustavo Miele – Goldman Sachs Group, Inc., Research Division
Mauricio Cepeda – Morgan Stanley, Research Division
Gustavo Tiseo – XP Investimentos Corretora de Câmbio, Títulos e Valores Mobiliários S.A., Research Division
Vitor Yonekura
Leandro Bastos – Citigroup Inc., Research Division
Presentation
Operator
Good morning, ladies and gentlemen. Welcome to Hypera Pharma’s Third Quarter of 2026 Results Conference Call. Today with us, we have Mr. Breno Oliveira, CEO; and Mr. Ramon Sanches, CFO and IRO. Today’s live webcast may be accessed through the company’s Investor Relations website at www.ri.hypera.com.br/en. We would like to inform you that this event is being recorded.
[Operator Instructions] We would also like to inform you that statements during this conference may constitute forward-looking statements. Such statements are subject to known and unknown risks and uncertainties that could cause the company’s actual results to differ materially from those set forth in the forward-looking statements.
Now I’ll turn the floor over to Mr. Breno Oliveira, who will begin the presentation. Mr. Breno, you may begin the conference.
Breno Pires de Oliveira
Chief Executive Officer
Good morning, everyone. It’s great to be here with you for an earnings call. Once again, we delivered sell-out growth along with market share gains in the categories where we operate. Our sell-out grew by 6.6%, while our target market grew by 5.4%. This quarter, our target market grew at a slower pace compared to the first half of this year, mainly due
